Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets.
Cardiac glycosides such as oleandrin are known to inhibit the Na,K-ATPase pump, resulting in a consequent increase in calcium influx in heart muscle. Here, we investigated the effect of oleandrin on the growth of human and mouse cancer cells in relation to Na,K-ATPase subunits. Oleandrin treatment resulted in selective inhibition of human cancer cell growth but not rodent cell proliferation, which corresponded to the relative level of Na,K-ATPase alpha3 subunit protein expression. Human pancreatic cancer cell lines were found to differentially express varying levels of alpha3 protein, but rodent cancer cells lacked discernable expression of this Na,K-ATPase isoform. A correlation was observed between the ratio of alpha3 to alpha1 isoforms and the level of oleandrin uptake during inhibition of cell growth and initiation of cell death; the higher the alpha3 expression relative to alpha1 expression, the more sensitive the cell was to treatment with oleandrin. Inhibition of proliferation of Panc-1 cells by oleandrin was significantly reduced when the relative expression of alpha3 was decreased by knocking down the expression of alpha3 isoform with alpha3 siRNA or increasing expression of the alpha1 isoform through transient transfection of alpha1 cDNA to the cells. Our data suggest that the relative lack of alpha3 (relative to alpha1) in rodent and some human tumor cells may explain their unresponsiveness to cardiac glycosides. In conclusion, the relatively higher expression of alpha3 with the limited expression of alpha1 may help predict which human tumors are likely to be responsive to treatment with potent lipid-soluble cardiac glycosides such as oleandrin.
Yang
Peiying
P
Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer, Houston, Texas 77054, USA.
Menter
David G
DG
Cartwright
Carrie
C
Chan
Diana
D
Dixon
Susan
S
Suraokar
Milind
M
Mendoza
Gabriela
G
Llansa
Norma
N
Newman
Robert A
RA
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D002298:Cardenolides / Q000378:metabolism / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D051379:Mice; D008856:Microscopy, Fluorescence; D021122:Protein Subunits / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000378:metabolism; D034741:RNA, Small Interfering; D000254:Sodium-Potassium-Exchanging ATPase / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014162:Transfection
D000970:Antineoplastic Agents; D002298:Cardenolides; D021122:Protein Subunits; D034741:RNA, Small Interfering; C499076:ATP1A1 protein, human; D000254:Sodium-Potassium-Exchanging ATPase; C021065:oleandrin